BNP (B-type Natriuretic Peptide) vs Cerebrolysin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BNP (B-type Natriuretic Peptide)
BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.
Full details →Cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from purified pig brain proteins. It is approved in many countries for stroke, traumatic brain injury, and dementia.
Full details →Side-by-Side Comparison
| Aspect | BNP (B-type Natriuretic Peptide) | Cerebrolysin |
|---|---|---|
| Dose Range | 25 mcg–100 mcg | 2150 mg–4300 mg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 1–4 weeks | 1–2 weeks |
| Route | subcutaneous | intramuscular |
| Mechanism | Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress. | Contains multiple neurotrophic factors that promote neuroplasticity, reduce neuronal apoptosis, and support synaptic function. Has both neurotrophic and neuroprotective properties. |
| Typical Dosage | Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure. | Clinical dosing: 10-30ml IV daily for acute conditions. Research use: 5-10ml IM daily for cognitive enhancement. Treatment courses typically last 10-20 days. |
| Administration | Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically. | Administered via intramuscular or intravenous injection. IV administration is typically used in clinical settings. IM can be used for research purposes. |
| Side Effects | Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients. | Generally well-tolerated. May cause dizziness, headache, sweating, or injection site reactions. Rare cases of agitation or confusion. |
| Best For |
What They Have in Common
BNP (B-type Natriuretic Peptide), Cerebrolysin are both commonly used for:
Key Differences
Unique to Cerebrolysin:
Which Has Stronger Evidence?
- Recovery & Healing: Cerebrolysin has stronger research support.
| Goal | BNP (B-type Natriuretic Peptide) | Cerebrolysin |
|---|---|---|
| Recovery & Healing | medium | high |
Key Studies
BNP (B-type Natriuretic Peptide)
- Developing a risk score for B-type natriuretic peptide (BNP) ≥ 100 pg/ml levels: the suita study.
BMC cardiovascular disorders, 2025
- Inhibition of Fap Promotes Cardiac Repair by Stabilizing BNP.
Circulation research, 2023
- Body Composition Measures and N-terminal pro-B-type Natriuretic Peptide (NT-pro-BNP) in US Adults.
Clinical chemistry, 2023
Cerebrolysin
- Cerebrolysin Ameliorates Age-Induced Dendritic Spine Degeneration and Memory Decline in C57BL6 Mice.
Neurochemical research, 2025
- Is Cerebrolysin Useful in Psychiatry Disorders?
Biomedicines, 2025
- Cerebrolysin ameliorates ketamine-mediated anxiety and cognitive impairments via modulation of mitochondrial function and CREB/PGC-1α pathway.
Molecular brain, 2025
Ready to Learn More?
Looking for trusted sources?